tiagabine has been researched along with midazolam in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Lambert, JD; Roepstorff, A | 1 |
| Rekling, JC | 1 |
| Danhof, M; Edelbroek, PM; Jonker, DM; Piotrovsky, VK; Vermeij, DA; Voskuyl, RA | 1 |
| Cantrell, FL; Himes, E; Ritter, M | 1 |
| Akman, CI; Cappell, J; Jette, N; VanPassel, L | 1 |
| Chuang, SH; Reddy, DS | 1 |
1 review(s) available for tiagabine and midazolam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for tiagabine and midazolam
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Factors contributing to the decay of the stimulus-evoked IPSC in rat hippocampal CA1 neurons.
Topics: Animals; Calcium; Electric Stimulation; Evoked Potentials; GABA-B Receptor Antagonists; gamma-Aminobutyric Acid; Hippocampus; In Vitro Techniques; Kinetics; Male; Microelectrodes; Midazolam; Nipecotic Acids; Pyramidal Cells; Rats; Rats, Wistar; Receptors, GABA-B; Synapses; Tiagabine | 1994 |
Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation.
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamates; Carbamazepine; Cell Death; Cells, Cultured; Chlordiazepoxide; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Ethosuximide; Felbamate; Gabapentin; gamma-Aminobutyric Acid; Glucose; Hippocampus; Hypoxia; Ischemia; Lamotrigine; Levetiracetam; Midazolam; Neurons; Neuroprotective Agents; Nipecotic Acids; Oxcarbazepine; Phenobarbital; Phenylcarbamates; Phenylenediamines; Phenytoin; Piracetam; Propylene Glycols; Rats; Rats, Wistar; Tiagabine; Triazines; Valproic Acid | 2003 |
Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction.
Topics: Allosteric Regulation; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drug Synergism; Electroencephalography; Epilepsy; GABA Modulators; Male; Mathematics; Midazolam; Models, Biological; Neurotransmitter Uptake Inhibitors; Nipecotic Acids; Rats; Rats, Wistar; Receptors, GABA-A; Signal Transduction; Tiagabine | 2003 |
Intentional overdose with tiagabine: an unusual clinical presentation.
Topics: Anticonvulsants; Drug Overdose; Female; Humans; Hypnotics and Sedatives; Midazolam; Middle Aged; Nervous System Diseases; Nipecotic Acids; Tiagabine; Treatment Outcome | 2004 |
Tiagabine-induced nonconvulsive status epilepticus in an adolescent without epilepsy.
Topics: Adolescent; Drug Overdose; Electroencephalography; Female; GABA Modulators; Humans; Infusions, Intravenous; Midazolam; Monitoring, Physiologic; Neurotransmitter Uptake Inhibitors; Nipecotic Acids; Status Epilepticus; Television; Tiagabine; Treatment Outcome | 2006 |
Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.
Topics: Animals; Anticonvulsants; beta-Cyclodextrins; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Hippocampus; In Vitro Techniques; Male; Membrane Potentials; Mice; Mice, Inbred C57BL; Midazolam; Neurosteroids; Patch-Clamp Techniques; Pregnanolone; Receptors, GABA-A; Seizures; Tiagabine | 2020 |